🇺🇸 FDA
Pipeline program

Deutetrabenazine Oral Capsule

STUDY20250619

Approved small_molecule active

Quick answer

Deutetrabenazine Oral Capsule for Tardive Dyskinesia is a Approved program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Tardive Dyskinesia
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials